Investment in drug development co to fetch Jubilant Life upto $22.6mn
Jubilant Life Sciences today said its US arm stands to receive up to USD 22.6 million following the acquisition of a drug development firm, in which it has an indirect investment, by a pharmaceutical company which was not named.
Mar 29, 2016, 15:36 PM IST
FDA upgrades Jubilant Life's US plant status
This upgradation by the USFDA from Official Action Indicated (OAI) to VAI is "indicative of the current good manufacturing practice (cGMP) status at the facility" since receiving the warning letter in 2013, the drug maker added.
Jun 12, 2015, 14:24 PM IST
